AKTS FY 2023 Earnings — Aktis Oncology, Inc. Revenue & Financial Results | Market Cap Arena

AKTSAktis Oncology, Inc.

$1B

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$35M

Net Income

-$29M

EPS (Diluted)

$0.00

Cash Flow

Operating Cash Flow

-$30M

Free Cash Flow

-$34M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$122M

Total Liabilities

$169M

Stockholders' Equity

-$46M

Cash & Equivalents

$30M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$35M	-$20M	-76.0%
Net Income	-$29M	-$18M	-59.7%